Pathos AI Licenses JSKN016 From Alphamab for $125 Million Upfront

Companies: Pathos AI & Alphamab Oncology · Event Type: Exclusive License (Ex-China) · Asset: JSKN016 (TROP2/HER3 Bispecific ADC) · Upfront: $125 Million · Milestones: Up to $2.093 Billion · Additional Structure: Warrant for Up to $62.5 Million Preferred Investment Summary Pathos AI licensed ex-China rights…